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ToxicityThe currently ﬁelded pre-hospital therapeutic regimen for the treatment of organophosphorus (OP) poisoning
in the United States (U.S.) is the administration of atropine in combination with an oxime antidote (2-PAM Cl)
to reactivate inhibited acetylcholinesterase (AChE). Depending on clinical symptoms, an anticonvulsant,
e.g., diazepam, may also be administered. Unfortunately, 2-PAM Cl does not offer sufﬁcient protection across
the range of OP threat agents, and there is some question as to whether it is the most effective oxime compound
available. The objective of the present study is to identify an oxime antidote, under standardized and comparable
conditions, that offers protection at the FDA approved human equivalent dose (HED) of 2-PAM Cl against tabun
(GA), sarin (GB), soman (GD), cyclosarin (GF), and VX, and the pesticides paraoxon, chlorpyrifos oxon, and pho-
rate oxon. Male Hartley guinea pigs were subcutaneously challenged with a lethal level of OP and treated at ap-
proximately 1 min post challenge with atropine followed by equimolar oxime therapy (2-PAM Cl, HI-6 DMS,
obidoxime Cl2, TMB-4, MMB4-DMS, HLö-7 DMS, MINA, and RS194B) or therapeutic-index (TI) level therapy
(HI-6 DMS, MMB4-DMS, MINA, and RS194B). Clinical signs of toxicity were observed for 24 h post challenge
and blood cholinesterase [AChE and butyrylcholinesterase (BChE)] activity was analyzed utilizing a modiﬁed
Ellman's method. When the oxime is standardized against the HED of 2-PAM Cl for guinea pigs, the evidence
from clinical observations, lethality, quality of life (QOL) scores, and cholinesterase reactivation rates across all
OPs indicated that MMB4 DMS and HLö-7 DMS were the two most consistently efﬁcacious oximes.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
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Organophosphorus (OP) compounds, including pesticides and
chemical warfare nerve agents (CWNAs), represent a threat to the gen-
eral population, not only as possible weapons of terrorism (Okumura
et al., 2005; Zurer, 1998; Hubbard et al., 2013; Baker, 2013; Dolgin,
2013), but also as chemicals that could be released from transportation
and storage facilities during industrial accidents. Given the rapid onset
of symptoms and toxicity of OP nerve agents, a quick-acting therapeutic
regimen that is efﬁcacious over the broad spectrum of OPs is needed. To
provide the most effective therapy, medical countermeasures must be
administered as soon as possible post-exposure.
The current U.S. therapy regimen includes the administration of
atropine in combination with the oxime acetylcholinesterase (AChE)
reactivator pralidoxime chloride (2-PAM Cl) (Inchem.org, 1989, 1999),
followed by the anticonvulsant diazepam depending on whether
convulsive symptoms are observed. This approach is accomplished
with the use of the DuoDote® autoinjector kit (Meridian Medicalthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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aspx#) by trained emergency medical services personnel. The
DuoDote® is a two-chambered, self-propelled syringe used for the in-
tramuscular (IM) injection of atropine (2.1 mg free base) and 2-PAM
Cl (600 mg) through the same needle.
Although the current treatment approach does protect against some
OP toxicities, this protection does not extend across all OP CWNAs,
i.e., it is not a broad-spectrum antidote (Worek and Thiermann, 2013;
Thiermann et al., 2013). Unfortunately, whenOP pesticides are included
as potential intoxicants, the spectrum of therapeutic effectiveness is
even less. Additionally, most leading oxime reactivators currently
availableworldwide, including 2-PAMCl, are ionizedwith a hydrophilic
bis-pyridinium quaternary backbone. As such, they are capable of
reactivating cholinesterases (ChEs) in peripheral tissues, but not in the
central nervous system (CNS) because they do not readily cross the
blood brain barrier (BBB) (Voicu et al., 2013; Shih et al., 2012). Conse-
quently, more effective oxime therapies, including a broader spectrum
of activity and/or the capacity to cross the BBB, are being investigated
to identify amore effective treatment than 2-PAMCl. As the only true an-
tidote, i.e., one that reactivates the target molecule AChE, a better oxime
therapy would improve the nation's medical response capabilities.
While many oxime compounds have already been synthesized
and tested for broad-spectrum efﬁcacy (Bajgar, 2010; Shih et al.,
2009; Voicu et al., 2013; Worek et al., 2007) as well as BBB penetra-
tion capabilities (Sit et al., 2011; Radić et al., 2012), an actual head-
to-head and rigorous comparison of efﬁcacy entailing quality of life
(QOL) evaluation after treatment, peripheral blood cholinesterase
reactivation, and lethality endpoints has been absent. The few stud-
ies to assess comparative efﬁcacy in animals have typically been
conﬁned only to oximes within the same chemical class or moiety
developed within a particular laboratory, rather than what is currently
approved and ﬁeldedworldwide. Since those studies are also often con-
ducted under non-standardized experimental conditions and lack other
methodological controls to increase scientiﬁc rigor, the unintentional
introduction of bias remains a possibility when interpreting the results.
The currently ﬁelded oximes 2-PAMCl (USA, UK, France), obidoxime
Cl2 (LüH-6; Germany, Netherlands), TMB-4 (trimedoxime bromide;
Israel), and HI-6 DMS (Canada, Sweden) are efﬁcacious against speciﬁc
OP CWNAs (Antonijevic and Stojiljkovic, 2007; Bajgar, 2004, 2009,
2010; Cabal et al., 2004; Calic et al., 2006; Delﬁno et al., 2009; Eyer
et al., 2008; Kassa, 1998, 2002, 2005; Kuca et al., 2007a, 2009; Lundy
et al., 2006). Although there are few studies assessing the efﬁcacies
of oximes against OP pesticides, obidoxime Cl2 is currently regarded
as the most efﬁcacious against pesticides (Worek et al., 2007). The
search for a centrally acting oxime to maintain brain AChE activity
has produced MINA and RS194B. MINA is a relatively small (molecu-
lar weight, or MW= 87.1 Da) AChE reactivator that has been shown
to improve survivability against GB (Rutland, 1958; Askew, 1956; Dultz
et al., 1957; Myers, 1959; Shih et al., 2009, 2010, 2012). RS194B
(MW = 213.3 Da) and has been shown to reactivate human AChE
in vitro and protect mice against VX, GB, and paraoxon (Radić et al.,
2012).
HLö-7, HI-6, and obidoxime are bis-pyridinium oximes, each con-
taining two charged pyridine rings (requisite in an oxime for optimal
reactivation of VX-inhibited AChE; Esposito et al., 2014) joined by a di-
methyl ether (−CH2−O−CH2−) linker (Fig. 1). The structural differ-
ences among HLö-7, HI-6, and obidoxime are in the number and
position(s) of aldoximes on the pyridine rings (Kuca et al., 2006;
Ekström et al., 2009). Also, one of the ring groups in HLö-7 and HI-6 is
an isonicotinamide, which was included in their original synthesis to
reduce toxicity (Oldiges and Schoene, 1970) but which, as molecular
dynamic studies suggest, may also enhance ChE reactivation (Maxwell
et al., 2008). HLö-7 and obidoxime are the most potent reactivators of
phosphonylated and phosphorylated AChE, respectively (Worek et al.,
2004). MMB4 and TMB-4 are the same 4-position bis-pyridinium
aldoxime, except that MMB4 has a -CH2- linker while TMB-4 (adibromide salt) has a -C3H6- linker. TMB-4 originated in 1958 and was
the ﬁrst bis-pyridinium oxime to be effective against GA (Schoene and
Oldiges, 1973; Inns and Leadbeater, 1983). The difference between
these two similar compounds in terms of toxicity to the Hartley guinea
pig by IM injection is remarkable: the 24-hour LD50 (median lethal
dose) is 679 mg/kg (1514 μmol/kg) for MMB4 DMS (unpublished
data), and 80 mg/kg (179 μmol/kg) for TMB-4 (Shih et al., 2009).
The overall objective of this study was to compare rigorously the
efﬁcacy of currently ﬁelded and select promising novel AChE oxime
reactivators under strict standardized experimental conditions to en-
able an accurate and unbiased assessment of their efﬁcacies against
OP CWNAs and pesticides. To accomplish this, the human equivalent
FDA-approved dose of 2-PAM Cl was used as the experimental standard
and the equimolar oxime therapy was administered to atropinized
guinea pigs after an LD85 challenge of each OP CWNA or pesticides
(data not shown). The LD85 was selected as the challenge level across
OPs because it maximized the power of the test to discriminate
among the oximes in terms of lethality. Additionally, those oximes
with a safety index greater than 2-PAM Cl, i.e., MMB4 DMS, HI-6 DMS,
MINA, and RS194B were also evaluated at an additional ‘therapeutic
dose’ level equal to themedian lethal dose (LD50) for the oxime divided
by the TI for 2-PAM Cl. Overall efﬁcacy was determined speciﬁcally
in terms of QOL, blood cholinesterase levels in 24-hour survivors, and
lethality.
Materials and methods
Organophosphorus compounds. The ﬁve CWNAs evaluated were
tabun (GA; O-ethyl N,N-dimethyl phosphoramidocyanidate),
sarin (GB; O-isopropyl methylphosphonoﬂuoridate), soman (GD;
O-pinacolyl methylphosphonoﬂuoridate), cyclosarin (GF, cyclohexyl
methylphosphonoﬂuoridate), and VX (O-ethyl S-(2-diisopropyl-
aminoethyl) methylphosphonothiolate). They were obtained from
the U.S. Army Edgewood Chemical Biological Center (Aberdeen
Proving Ground, MD). The purity values of the CWNAs were N98.5%
as determined by gas chromatography. Chlorpyrifos oxon (purity
≥98%) and paraoxon (purity ≥98%) were purchased from Chem
Service, Inc, West Chester, PA. Phorate oxon (purity ≥97.1%) was syn-
thesized at Battelle's Analytical Chemistry Development Department
(Columbus, OH). GB, GD, GF, and VX were diluted in 0.9% saline; GA
and phorate oxon were diluted in multisol (a biocompatible solution
of 48.5%water, 40% propylene glycol, 10% ethanol, and 1.5% benzyl alco-
hol, all v/v); and chlorpyrifos oxon and paraoxon were diluted in etha-
nol (99.96%), with the dosing solution concentration of each pesticide
being limited to that which would allow the total volume of ethanol
injected to be no more than 0.06% (v/w) of the body mass.
Oximes. 2-PAM Cl (pralidoxime chloride, 2-hydroxyiminomethyl-
1-methylpyridinium chloride; supplied as an injectable drug at
100 mg/mL) and MMB4 DMS (methoxime dimethanesulfonate;
1,1-methylene bis[4(hydroxyimino) methyl]pyridinium) dimeth-
anesulfonate; purity 100%) were supplied by the U.S. Department
of Defense. HI-6 DMS (4-carbamoyl-1-[({2-[(E)-(hydroxyimino)
methyl)]pyridinium-1-yl}methoxyl)methyl] pyridinium dimesylate;
purity 98.7%), MINA ((1E)-1-(hydroxyimino)propan-2-one; purity
98.7%), TMB-4 (trimedoxime bromide; 1′-propane-1,3-diylbis{4-[(E)-
(hydroxyimino)methyl]pyridinium} dibromide; purity 98.5%), and
HLö-7 DMS (pyridinium,1-(((4-(aminocarbonyl) pyridinio)methoxy)
methyl)-2,4-bis((hydroxyimino)methyl), dimesylate; purity 96.73%)
were procured from Southwest Research Institute, San Antonio,
TX. RS194B (N-(2-(azepan-1-yl)ethyl)-2-(hydroxyimino)acetamide;
purity 96± 2%) was procured from Skaggs School of Pharmacy & Phar-
maceutical Sciences (University of California, San Diego). Obidoxime
Cl2, LüH-6 (oxo-[[1-[[4-(oxoazaniumylmethylidene)pyridin-1-yl]
methoxymethyl]pyridin-4-ylidene]methyl]azanium dichloride; purity
97.1%) was procured from Sigma Aldrich. MMB4 DMS, HI-6 DMS,
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Fig. 1. Structures of eight oximes tested and atropine free base.
256 C.M. Wilhelm et al. / Toxicology and Applied Pharmacology 281 (2014) 254–265MINA, TMB-4, HLö-7 DMS, and obidoxime Cl2 were formulated as dos-
ing solutions for intramuscular (IM) injection in normal (0.9%, w/v) sa-
line. RS194B was prepared as per supplier instruction by dissolving in a
mixture of concentrated (37%, w/w) hydrochloric acid diluted 1:1 (v/v)
with distilled water, and adjusting the ﬁnal oxime solution to pH 7
using 6.25% (w/v) aqueous sodium hydroxide. This brought the sodium
chloride concentration in the RS194B solution to 1.6%, w/v.Chemical analysis. The concentrations of the OP agent stock solutions
were checked by gas chromatography (GC) using an Agilent 6890 GC
equipped with a ﬂame photometric detector (FPD) in phosphorus
mode, prior to and after administration. Additionally, OP pesticides
and oxime analysis was performed by high performance liquid chroma-
tography (HPLC) using an Agilent 1200 series LC and ultraviolet (UV)
detector to conﬁrm solution concentration. Prior to use on study, each
oxime was determined to be stable for the concentrations required on
study at both room temperature (25 °C) and within refrigeration
(4 °C) for 96 h. Chemical veriﬁcation and concentration analysis of
atropine (King Pharmaceuticals, St. Louis, MO, Batch #RP-526-1)
were performed using HPLC. Target dosing concentrations were pre-
pared at 259 mg/mL (equimolar) and 400 mg/mL (TI) for MMB4 DMS,
270 mg/mL (equimolar) and 400 mg/mL (TI) for HI-6 DMS, 50 mg/mL
(equimolar) and 100 mg/mL (TI) for MINA, 100 mg/mL (equimolar)
and 500 mg/mL (TI) for RS194B, 102 mg/mL 2-PAM Cl, 205 mg/mL
obidoxime Cl2, 63 mg/mL TMB-4, and 302 mg/mL HLö-7 DMS.Preparation of animals. Male Hartley guinea pigs were purchased from
Charles River (Raleigh, NC & Saint-Constant, QC, Canada) and utilized
in accordancewith protocol speciﬁcations approved by the Institutional
Animal Care and Use Committee (IACUC). The guinea pig was selected
based on having low levels of plasma carboxylesterase relative to
other rodent species, which is more similar to humans (Bahar et al.,
2012), similarity of AChE protein sequence to that of humans
(Cadieux et al., 2010), affordability, and historical use. Animals were
quarantined for 3 to 5 days prior to randomization by body weight.
Body weights, used to determine challenge doses and treatment vol-
umes, were taken the day prior to challenge. Weights ranged from
250 to 500 g with a mean of 330 g among the 1920 guinea pigs placed
on study. Baseline bloodswere also collected via the vena cava in chilled
K3 EDTA (Covidien, Mansﬁeld, MA) tubes and processed to determine a
baseline AChE and BChE activity in whole blood.
OP challenges and oxime therapies. On the day of study, guinea pigswere
injected subcutaneously (SC) to ensure an accurate exposure level, with
vehicle or an LD85 dose of one OP (Table 1) via a 29G ½″ needle/syringe
system between the scapulae. OPs were administered in vehicle at the
LD85 dose after atropine only treatment as determined in preparatory
work (Table 2a). An LD85 was selected as the optimal challenge level
across all OPs as this exposure level maximizes the ability to discrimi-
nate among oxime efﬁcacies in terms of lethality while conserving
resources. Power calculations were performed to ensure group size
was sufﬁcient for 80% statistical power between oxime groups. At
Table 1
Treatment groups study design.
Group SC injection at t = 0 min
(between scapulae)
IM injection at t = 1 ± 0.25 min (right thigh) IM injection immediately post
atropine (left thigh)
OP OP vehicle Atropine, free base 0.4 mg/kg Atropine vehicle, 0.25 mL/kg Oxime Oxime vehicle
1 – X – X – X
2 – X – X X –
3 X – X – – X
4 X – X – X –
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base/kg from a solution of 1.64 mg atropine free base/mL) was given
IM immediately followed by treatment with either an oxime in vehicle
or vehicle. Both administrations were via a 29G ½″ needle/syringe sys-
tem in contralateral thighs. An atropine free base level of 0.4 mg/kg in
the guinea pig was selected for this study based on the body surface
area-corrected equivalent dose given to a human victim of OP poisoning
in a ﬁrst responder setting after administration of three DuoDote®
autoinjectors (USD HHS, FDA, CDER, 2005) - cited in USDHHS, 2005.
The FDA recommends that no more than three injections be adminis-
tered to victims without adequate supportive care, e.g., ventilator assis-
tance. Oximes, 2-PAM Cl, MMB4 DMS, HI-6 DMS, MINA, RS194B,
obidoxime Cl2, HLö-7 DMS, with the exception of TMB-4, were adminis-
tered at the equimolar dose of 2-PAM Cl available in three DuoDote®
autoinjectors given to a 70-kg human, equivalent to 25.7 mg/kg
(146 μmol/kg) in guinea pigs (Table 2b). Due to toxicity concerns,
only TMB-4 could not be administered at the equimolar level. The ther-
apy level for TMB-4 was revised based on the approved human dose of
2.56 μmol/kg and converted to 11.8 μmol/kg based on the FDA conver-
sion factor for guinea pigs (4.6 to adjust for body surface area, guinea
pig/human, USDHHS, 2005). This was equivalent to 5.26 mg/kg then
multiplied by three autoinjectors (maximum pre-hospital dose) for a
ﬁnal dose of 15.8 mg/kg (35 μmol/kg). HI-6 DMS, MMB4 DMS, RS194B
andMINAwere evaluated at an additional dose level equal to themedi-
an lethal dose (LD50) for the oxime divided by the Therapeutic Index
(TI) for 2-PAM Cl (Table 2c). Speciﬁcally, TI2-PAM Cl is the ratio of the 24-
h LD50 (168 mg/kg; Fleisher et al., 1970) to the FDA-approved human
therapeutic dose (i.e., median effective dose, ED50 = 25.7 mg/kg;
Koplovitz et al., 1992) or
TI2−PAM Cl ¼
LD50 2‐PAM Cl; IM in guinea pigsð Þ
ED50 2‐PAM Cl; IM in guinea pigsð Þ
¼ 168mg=kg
25:7mg=kg
¼ 6:53
The TI-based dose level for those oximeswould be determined using
the following method
TI‐based DLoxime ¼
LD50;oxime
6:53
or 15.3% of the LD50,oxime.
Clinical observations were recorded for 24 h post challenge by indi-
viduals not involved in challenges. Terminal blood samples were col-
lected and processed for all survivors using Hemoglobind™ (McGarryTable 2a
Dose levels for OPs in atropinized guinea pig.
OP OP dose level (LD85)
Tabun (GA) 240 μg/kg
Sarin (GB) 52 μg/kg
Soman (GD) 49 μg/kg
Cyclosarin (GF) 75 μg/kg
VX 8 μg/kg
Chlorpyrifos oxon 100 mg/kg
Paraoxon 3.37 mg/kg
Phorate oxon 2.48 mg/kget al., 2013). For each animal, the relative AChE activity level (RAAChE)
was calculated as the Ellman assay acetylthiocholine turnover rate in a
terminal blood sample divided by the turnover rate in the baseline
blood sample (Ellman et al., 1961). A similar calculation was made
using butyrylthiocholine turnover rates to determine RABChE for each
surviving guinea pig. Cholinesterase activitywas normalized to the indi-
vidual animal's baseline to determine RAAChE and RABChE, which were
compared using t-tests.
Quality of life assessment. A QOL scoring system was used to provide an
objective value for the clinical signs observed. Increasing scoreswere in-
dicative of a decrease in the QOL. QOL scoreswere calculatedwith group
averages at each time-point. The signs and scores associated with the
signs are described in Table 3. For the impaired and mild signs, if any
of the listed signs were present for that classiﬁcation (e.g., ataxic,
miosis), then the score for that classiﬁcation was assigned a value of 1
regardless of the presence/absence of other signs in that classiﬁcation.
Moderate and severe signs were scored individually and not as a
group. For any time period in which the animal was still alive to include
moribund, the highest score that an animal could attain was 11. If death
was recorded at any time-point, the total score for that period was
assigned a value of 12. The lower the animal's QOL score, the closer its
exhibited behaviorwas to that prior to challenge. QOL scoreswere com-
pared using non parametric Wilcoxon Mann Whitney tests. Fisher's
exact tests at a one-sidedα=0.05 decision level were used to contrast
lethality between control and each treatment group.
Results
Effects of OPs at LD85 challenges in positive control animals
Clinical signs of cholinesterase intoxication for control OP animals
began within 5 min post challenge for all G agents, CPO, and phorate
oxon and by 30 min post challenge for VX and paraoxon. In all OP con-
trol animals, salivation or lacrimation, ataxia, fasciculations, respiratory
distress, tremors, and prostration were themost prevalent signs. Target
LD85 challenges successfully produced lethality between 73% and 100%
for all OPs except VX. The lethality among VX control animals was
only 52% (50/96).
Mitigation of the effects of OPs at LD85 challenges by oxime therapies
In Tables 4 through 10, the oxime treatment results for each OP
are listed in order of increasing lethality. Signiﬁcant oxime-related
effects (p b0.05) are indicated with an asterisk. It should be noted
that no signiﬁcant decrease in lethality was seen when treating an-
imals with the equimolar dose relative to the TI dose. However,
minor differences were observed in lethality and QOL for select
agents when treated with a TI dose of MMB4 DMS, HI-6 DMS or
MINA.
Tabun (GA)
Treatment of GA-challenged animals with either MMB4 DMS or
HLö-7 DMS reduced lethality to 13%, signiﬁcantly less than the
Table 2b
Therapy levels of oxime treatments.
Oxime Oxime equimolar therapy level IM LD50 (μmol/kg) Therapy level as a portion of LD50 IM LD50 Ref.
(mg/kg) (μmol/kg)
2-PAM Cl 25.7 146 951 15% Fleisher et al. (1970)
MMB4 DMS 65.3 146 1514 10% Unpublished
HI-6 DMS 69.6 146 1498 10% Unpublished
MINA 12.7 146 2492 6% Unpublished
RS194B 31.0 146 3849 4% Unpublished
Obidoxime Cl2 52.3 146 220 66% Fleisher et al. (1970)
TMB-4 15.8 35 179 20% Shih et al. (2009)
HLö-7 DMS 75.9 146 993 15% Eyer et al. (1992)
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duced the occurrence of respiratory distress and prostration, with
MMB4 DMS-treated animals primarily exhibiting only ataxia be-
tween 1 and 8 h post challenge. Although lethality for GA-
challenged animals treated with TMB-4 was 100%, the clinical pre-
sentations of respiratory distress and prostration were reduced.
MMB4 DMS and HLö-7 DMS treatment resulted in QOL scores that
were signiﬁcantly reduced in treatment group animals compared
to control group animals from 30 min post challenge through the
24 hour observation. Although other oximes provided some beneﬁt
at various time points, only MMB4 DMS and HLö-7 DMS treatment
limited clinical signs to the mild or moderate classiﬁcation at the
24 hour observation time point. As shown in Table 4, MMB4 DMS-
treated animals exhibited relatively uninhibited activity for both
AChE and BChE (greater than 70%) at 24 h post challenge. This activ-
ity level for both ChEs was more than 20% higher than the activity
level of the GA-challenged control animals. Only MMB4 DMS and
HI-6 DMS offered greater mitigation of OP effects when the oximes
were given at TI-based levels relative to equimolar levels. Both pro-
vided signiﬁcant ChE reactivation and MMB4 DMS animals were
asymptomatic at the 24 hour observation.Sarin (GB)
All GB-challenged animals survived when treated with either
MMB4 DMS or 2-PAM Cl, and the effect was signiﬁcant (p b0.05)
relative to the 73% lethality obtained in the control animals
(Table 5). The oxime therapy in these two groups resulted in the
majority of animals returning to normal by 24 h post challenge.
Both oximes delayed the time to onset of signs by 25 min and re-
duced the frequencies of respiratory distress and prostration.
MMB4 DMS, 2-PAM Cl, and HI-6 DMS provided sufﬁcient protection
against GB that QOL scores in treatment group animals compared to
control group animals were signiﬁcantly reduced from 30 min post
challenge through the 24 hour observation. Although other oximes
provided some statistical signiﬁcance at various time-points, only
MMB4 DMS and 2-PAM Cl treatment resulted in QOL scores at the
minimal “impaired” level at the 24 hour observation time point. 2-
PAM Cl, MMB4 DMS, HI-6 DMS, and TMB-4 signiﬁcantly mitigated
both AChE and BChE inhibition. As shown in Table 5, only MINA
had signiﬁcant improvement of therapy at the TI dose with zero le-
thality and animals being asymptomatic at the 24 hour observation.Table 2c
TI dose levels of select oxime treatments.
Oxime n 24-h Toxicity (mg/kg) Probit slope
LD50 95% LCL 95% UCL
MMB4 DMS 26 679 635 944 21
HI-6 DMS 31 717 659 766 31
MINA 31 217 191 243 15
RS194B 21 821 733 916 24Soman (GD)
When tested against a GD challenge, none of the oximes tested
showed any signiﬁcant differences in themeasured endpoints between
the treatment and control groups (data not shown). Itmay be of interest
that HLö-7 DMS delayed the time to onset of signs by 25 min, although
none of the animals in this group survived to the 24 hour post challenge
time point.
Cyclosarin (GF)
Treatment of GF-challenged animals with MMB4 DMS signiﬁ-
cantly reduced lethality to 13% compared to the 89% lethality in the
control group (Table 6). In addition, half of the MMB4 DMS-treated
animals became asymptomatic by 24 hour post challenge. MMB4
DMS also reduced the frequency of salivation/lacrimation, fascicula-
tions, tremors, and prostration as compared to control animals.
MMB4 DMS provided sufﬁcient protection against GF that QOL
scores in treatment group animals compared to control group ani-
mals were signiﬁcantly reduced from 30 min post challenge through
the 24 hour observation, when signs were mild to moderate in sever-
ity. MMB4 DMS offered statistically signiﬁcant reactivation of both
AChE and BChE. HI-6 DMS also provided signiﬁcant reactivation;
however those survivors, as well as the HLö-7 DMS survivors, had
QOL scores that reﬂected moderate to severe signs at the end of the
observation period. No improvements in therapy were seen with
the TI dose with any of the oximes.
VX
Although VX lethality in controls was only 52%, themodel was able to
detect signiﬁcant efﬁcacy and differentiate among the oximes. The LD85
of VX used in this study was based on a dose/lethality probit curve with
a slope of 34 (p = 0.041), determined in preparation for this work
(data not shown). All animals treated with 2-PAM Cl, MMB4 DMS, HLö-
7 DMS, or TMB-4 survived. Treatmentwith those oximes, aswell as treat-
ment with obidoxime Cl2, resulted in QOL scores at the minimal “im-
paired” level (i.e., ataxia) at the 24 hour observation time point.
Although the 24 hour QOL scores for both TMB-4 and obidoxime Cl2 ap-
peared to be low, the means were not statistically different from that
for the control animals due to an inadvertently low challenge level across
all groups. Animal groups treated with those oximes had statisticallyTI-based therapy level
(mg/kg)
Equimolar therapy level
(mg/kg)
TI-based/equimolar ratio
104 65.3 1.6
110 69.6 1.6
33 12.7 2.6
126 31.0 4.1
Table 3
Quality of life (QOL) scoring system.
Classiﬁcation of signs Signs Weighted score
Normal N/A 0
Impaired Hunched posture 1
Lethargic
Ataxic
Weak
Chewing
Miosis
Mydriasis
Mild Fasciculations 1
Lacrimation
Nystagmus
Salivation
Hyperaesthetic
Other (comment)
Moderate Tremors 1
Severe Convulsions 2
Non-responsive 2
Prostration 2
Respiratory distressa 2
Terminal Moribund or found dead 12
Abbreviation: N/A, not applicable.
a Includes any severe respiratory related signs (i.e., shallow respirations, abdominal
respirations, deep abdominal respirations, labored respirations, labored and audible
respirations, agonal breathing).
Table 4
Summary of oximes challenged with GA.
Oxime dose Oxime Oxime dose (mg/kg) 24-h Lethality
Equimolar MMB4 DMS 65.3 1/8a
HLö7 DMS 75.9 1/8a
Obidoxime 52.3 2/8a
HI-6 DMS 69.6 3/8a
2 PAM Cl 25.7 6/8
RS194B 31 7/8
MINA 12.7 7/8
TMB4 15.8 8/8
None 0.0 55/64 = 86%
Therapeutic MMB4 DMS 104 0/8a
HI-6 DMS 110 0/8a
MINA 33.2 5/8
RS194B 126 6/8
None 0.0 28/32 = 88%
a Statistically signiﬁcant at the 0.05 level compared to the control group.
b Pooled across 64 animals challenged as equimolar controls with GA.
c Pooled across 32 animals challenged as TI controls with GA.
Table 5
Summary of oximes challenged with GB.
Oxime dose Oxime Oxime dose (mg/kg) 24-h Lethality
Equimolar MMB4 DMS 65.3 0/8a
2 PAM Cl 25.7 0/8a
HI-6 DMS 69.6 1/8a
HLö7 DMS 75.9 2/8a
RS194B 31 2/8a
Obidoxime 52.3 3/8
MINA 12.7 3/8
TMB4 15.8 4/8
None 0.0 47/64 = 73%
Therapeutic MINA 33.2 0/8a
MMB4 DMS 104 1/8a
RS194B 126 3/8a
HI-6 DMS 110 3/8a
None 0.0 29/32 = 91%
a Statistically signiﬁcant at the 0.05 level compared to the control group.
b Pooled across 64 animals challenged as equimolar controls with GB.
c Pooled across 32 animals challenged as TI controls with GB.
259C.M. Wilhelm et al. / Toxicology and Applied Pharmacology 281 (2014) 254–265signiﬁcant reactivation of AChE compared to the control group animals
(Table 7). All animals treated with 2-PAM Cl were normal at every
observation, and those treated with MMB4 DMS exhibited reduced
frequencies of fasciculations, respiratory distress, and prostration.
Both oximes provided adequate therapy for animals to be asymp-
tomatic by the 24 hour observation. Additionally, with the TI dose
of MINA, zero lethality was reported with improvement in the
QOL score at 24 h.Chlorpyrifos oxon (CPO)
Treatment of CPO-challenged animals with obidoxime Cl2, MMB4
DMS, HLö-7 DMS, and 2-PAM Cl signiﬁcantly reduced lethality in the
treatment group animals to ≤38% compared to 78% in the control
group animals (Table 8). Additionally, obidoxime Cl2, MMB4 DMS,
HLö-7 DMS, 2-PAM Cl, and RS194B signiﬁcantly reduced the fre-
quencies of lacrimation, fasciculations, respiratory distress, and
prostration. Obidoxime Cl2, MMB4 DMS, and HLö-7 DMS treatment
signiﬁcantly improved QOL scores in treatment groups compared
to the control group at 24 h post challenge, at which time clinical
signs in the treatment groups were limited to the mild and moderate
categories. Among the oximes offering signiﬁcantly improved sur-
vivability, only obidoxime Cl2 also provided statistically signiﬁcant24-h Mean QOL Score 24-h Mean RAAChE (%) 24-h Mean RABChE (%)
2.0a 71a 73
2.5a 41 50
3.5 33 26
5.6 52 59
9.6 22 35
10.6 32 37
11.3 28 53
12.0 – –
10.8b 35 49
0.0a 75a 110a
1.3a 53a 58a
8.9 25 34
9.8 33 47
11c 24 33
24-h Mean QOL Score 24-h Mean RAAChE (%) 24-h Mean RABChE (%)
0.5a 92a 78a
0.4a 69a 89a
2.8a 84a 79a
3.1a 67a 70a
3.1a 43 56
5.1a 80a 83a
6.9 25 38
6.6 53a 63
9.8b 28 42
0.0a 48a 56
2.8a 84a 94a
4.5a 74a 74a
5.8 74a 76a
11.3c 19 29
Table 6
Summary of oximes challenged with GF.
Oxime dose Oxime Oxime dose (mg/kg) 24-h Lethality 24-h Mean QOL Score 24-h Mean RAAChE (%) 24-h Mean RABChE (%)
Equimolar MMB4 DMS 65.3 1/8a 2.4a 88a 97a
HI-6 DMS 69.6 2/8a 5.0a 65 57
HLö7 DMS 75.9 2/8a 5.4a 51 59
2 PAM Cl 25.7 6/8 10.3 35 67
MINA 12.7 6/8 10.6 19 29
TMB4 15.8 7/8 10.5 74 85
Obidoxime 52.3 7/8 11.3 48 70
RS194B 31 7/8 11.9 23 37
None 0.0 57/64 = 89% 11.1b 36 50
Therapeutic MMB4 DMS 104 3/8a 6.0 82a 95a
HI-6 DMS 110 3/8a 6.6a 53a 57a
MINA 33.2 5/8 8.6 32 39
RS194B 126 7/8 11.4 40 52
None 0.0 27/32 = 84% 10.9c 23 35
a Statistically signiﬁcant at the 0.05 level compared to the control group.
b Pooled across 64 animals challenged as equimolar controls with GF.
c Pooled across 32 animals challenged as TI controls with GF.
Table 7
Summary of oximes challenged with VX.
Oxime dose Oxime Oxime dose (mg/kg) 24-h Lethality 24-h Mean QOL Score 24-h Mean RAAChE (%) 24-h Mean RABChE (%)
Equimolar 2 PAM Cl 25.7 0/8a 0.0a 86a 87a
MMB4 DMS 65.3 0/8a 0.0a 104a 93a
HLö7 DMS 75.9 0/8a 1.0a 73a 77
TMB4 15.8 0/8a 1.0 68a 67
Obidoxime 52.3 1/8a 1.5 92a 96a
HI-6 DMS 69.6 2/8 3.6a 103a 94a
MINA 12.7 2/8 3.8 49 64
RS194B 31 4/8 7.0 53 57
None 0.0 33/64 = 52% 6.9b 46 62
Therapeutic MMB4 DMS 104 0/8a 0.3a 96a 97a
MINA 33.2 0/8a 0.9a 53 64
HI-6 DMS 110 2/8 3.8 85a 75a
RS194B 126 3/8 6.0 69a 64
None 0.0 17/32 = 53% 7.8c 44 52
a Statistically signiﬁcant at the 0.05 level compared to the control group.
b Pooled across 64 animals challenged as equimolar controls with VX.
c Pooled across 32 animals challenged as TI controls with VX.
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ChE activities, statistical signiﬁcance could not be determined.
Paraoxon and phorate oxon (PHO)
When treated with 2-PAM Cl, HLö-7 DMS, obidoxime Cl2, or MMB4
DMS, the lethality for the pesticides paraoxon and phorate oxon wereTable 8
Summary of oximes challenged with chlorpyrifos oxon.
Oxime dose Oxime Oxime dose (mg/kg) 24-h Lethality
Equimolar MMB4 DMS 65.3 1/8a
Obidoxime 52.3 1/8a
HLö7 DMS 75.9 2/8a
2 PAM Cl 25.7 3/8
RS194B 31 4/8
TMB4 15.8 5/8
HI-6 DMS 69.6 6/8
MINA 12.7 7/8
None 0.0 50/64 = 78%
Therapeutic MMB4 DMS 104 0/8a
RS194B 126 2/8a
MINA 33.2 5/8
HI-6 DMS 110 5/8
None 0.0 27/32 = 84%
a Statistically signiﬁcant at the 0.05 level compared to the control group.
b Pooled across 64 animals challenged as equimolar controls with chlorpyrifos oxon.
c Pooled across 32 animals challenged as TI controls with chlorpyrifos oxon.signiﬁcantly reduced to rates between 0 and 25%. HI-6 DMS and
TMB-4 also provided signiﬁcant protection against paraoxon with
13% and 25% lethality, respectively. Control group animals challenged
with paraoxon and phorate oxon had lethality of 84% and 97%, respec-
tively (Tables 9 and 10). There was also a signiﬁcant reduction in
frequencies of salivation, fasciculations, respiratory distress, and pros-
tration with 2-PAM Cl, HLö-7 DMS, obidoxime Cl2, or MMB4 DMS.24-h Mean QOL Score 24-h Mean RAAChE (%) 24-h Mean RABChE (%)
2.4a 37 19
1.8a 43 17
3.1a 19 11
4.5 92a 68a
7.0 37 37
8.5 43 10
9.9 14 8
10.5 60 76
10.1b 13 8
0.5a 19 8
4.3a 9 3
7.6 11 4
8.9 7 3
10.3c 9 4
Table 9
Summary of oximes challenged with paraoxon.
Oxime dose Oxime Oxime dose (mg/kg) 24-h Lethality 24-h Mean QOL Score 24-h Mean RAAChE (%) 24-h Mean RABChE (%)
Equimolar 2 PAM Cl 25.7 0/8a 0.1a 49a 45a
HLö7 DMS 75.9 0/8a 1.0a 38 30
Obidoxime 52.3 1/8a 1.5a 80a 47a
MMB4 DMS 65.3 1/8a 2.3a 71a 52a
HI-6 DMS 69.6 1/8a 3.3a 25 19
TMB4 15.8 2/8a 4.9a 52a 31
MINA 12.7 7/8 11.3 16 14
RS194B 31 8/8 12.0 – –
None 0.0 54/64 = 84% 10.8b 23 21
Therapeutic MMB4 DMS 104 0/8a 0.0a 35 22
HI-6 DMS 110 5/8 8.6 26 19
RS194B 126 5/8 7.6 16 11
MINA 33.2 7/8 11.3 5 4
None 0.0 28/32 = 88% 11.1c 13 7
a Statistically signiﬁcant at the 0.05 level compared to the control group.
b Pooled across 64 animals challenged as equimolar controls with paraoxon.
c Pooled across 32 animals challenged as TI controls with paraoxon.
Table 10
Summary of oximes challenged with phorate oxon.
Oxime dose Oxime Oxime dose (mg/kg) 24-h Lethality 24-h Mean QOL Score 24-h Mean RAAChE (%) 24-h Mean RABChE (%)
Equimolar HLö7 DMS 75.9 0/8a 0.1a 64a 61
Obidoxime 52.3 0/8a 1.1a 75a 48
2 PAM Cl 25.7 1/8a 1.5a 48 50
MMB4 DMS 65.3 2/8a 3.0a 64a 55
TMB4 15.8 6/8 9.6 67a 52
HI-6 DMS 69.6 7/8 10.6 48 44
RS194B 31 7/8 11.3 47 49
MINA 12.7 8/8 12.0 – –
None 0.0 62/64 = 97% 11.8b 32 36
Therapeutic MMB4 DMS 104 1/8a 1.5a 82 56
HI-6 DMS 110 5/8 8.3 50 43
RS194B 126 7/8 10.5 52 53
MINA 33.2 8/8 12.0 – –
None 0.0 32/32 = 100% 12.0 – –
a Statistically signiﬁcant at the 0.05 level compared to the control group.
b Pooled across 64 animals challenged as equimolar controls with phorate oxon.
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Fig. 2. 24-hour Lethality for each OP/oxime equimolar combination.
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obidoxime Cl2, or MMB4 DMS were signiﬁcantly reduced relative to
the control animals at 24 h post challenge, with oxime-treated animals
showing only impaired to moderate signs. Against paraoxon, MMB4
DMS and TMB-4 provided reactivation of both ChEs, while HLö-7 DMS
reactivated only AChE, relative to control animals. There was no signif-
icant difference in cholinesterase activity of survivors within the pho-
rate oxon-challenged animals at 24 h.
Fig. 2 presents the 24-hour lethality data collated across the
eight OPs tested, and illustrates thatMMB4DMS andHLö-7DMSoffered
protection against all OPs except GD, and that 2-PAM Cl and obidoxime
Cl2 were effective against all but GD, GF, and (for 2-PAM Cl) GA. A
comparison with the equimolar (Fig. 2) and TI lethality (Fig. 3) shows
that no signiﬁcant difference is seen in the lethality results for any
agents except a slight improvement for GB when treating with MINA.
Fig. 4 presents the mean equimolar QOL scores at the 24-hour observa-
tion, and is consistent with the efﬁcacy pattern of the lethality data.
Fig. 5 collates the complement of the equimolar relative AChE activity
at 24 h (100− RAAChE= relative AChE inhibition) in order to represent
effective oximeswith short bars, as in Figs. 3 and 4. A similar plot for the
equimolar 24-hour BChE is presented in Fig. 6. The fact that ChE activity
in the blood did not correlate well with lethality can be seen by con-
trasting Figs. 5 and 6 with Fig. 3.
There was a clear division of oxime efﬁcacy in animals challenged
with tabun (GA), cyclosarin (GF), and phorate oxon (PHO). Against GA
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Fig. 3. 24-hour Lethality for each OP/oxime TI combination.
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Fig. 5.Mean 24-hour peripheral blood acetylcholinesterase relative inhibition for each
OP/oxime equimolar combination.
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signiﬁcant protection against lethality (lethality ≤38%) relative to con-
trol animals, while obidoxime Cl2 was statistically signiﬁcant against le-
thality (25% lethality) only for GA. MMB4-DMS, HLö-7 DMS, 2-PAM Cl,
and obidoxime Cl2 showed statistically signiﬁcant protection against le-
thality (lethality≤38%) against both phorate oxon and CPO-challenged
animals. All other oximes (TMB-4, RS194B, and MINA), when used as
therapy against GA, GF, CPO, or phorate oxon, demonstrated low efﬁca-
cy with generally ≥50% lethality.
GB andVXhadmuchhigher ChE reactivation rates and nomore than
50% lethality in all oxime-treated groups. For oxime therapy against GB,
MMB4-DMS, HLö-7 DMS, HI-6 DMS, 2-PAMCl, and RS194B all exhibited
statistically signiﬁcant improvement in lethality relative to the controls.
In pesticide oxon-challenged animals, MMB4-DMS, HLö-7 DMS, and
obidoxime Cl2 were each signiﬁcantly efﬁcacious relative to lethality in
control animals. Obidoxime Cl2 demonstrated the best overall protection0
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Fig. 4.Mean 24-hour quality of life score for each OP/oxime equimolar combination.for pesticide oxons with signiﬁcant ChE reactivation, improvement in
QOL scores, and survival through the 24 hour period. Obidoxime Cl2 has
been shown to be one of the most efﬁcacious reactivators against OP
pesticides by other laboratories (Worek et al., 2007), and, in the present
study, the oxime performed well against the nerve agents GA, GB, and
VX as well.
MMB4 DMS and HLö-7 DMS were the two most consistently efﬁca-
cious oximes across all challengeOPs.MMB4DMS treatment resulted in
an average 80% survivability while HLö-7 DMS treatment resulted in an
average of 77%. The 24 hour average QOL score was ≤3.0 for MMB4
DMS and ≤5.4 for HLö-7 DMS on a 0 to 12 scale, excluding GD data.
Additionally, reactivation of both AChE and BChE was more than
50% with MMB4 DMS for all OP challenges with the exception of chlor-
pyrifos oxon and GD. Peripheral blood ChE inhibition by GF and VXwas0
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Fig. 6.Mean 24-hour peripheral blood butyrylcholinesterase relative inhibition for each
OP/oxime equimolar combination.
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vation at 88 to 100%. Reactivation of AChE and BChE among survivors
with HLö-7 DMS was not as signiﬁcant when compared to that of
MMB4 DMS; however, both enzymes were reactivated above 30% for
all OPs with the exception of chlorpyrifos oxon and GD.
Discussion
Oxime efﬁcacy is an amalgamation of somewhat unrelated physico-
chemical and pharmacologic factors. A favored, effective oxime has a
relatively high therapeutic/safety index, quickly biodistributes to organs
targeted by OPs (Voicu et al., 2013), effectively reactivates inhibited
AChEwithin those target organs, and ensures permanent rapid elimina-
tion of the poison. Many research articles have discussed the merits of
particular reactivator compounds against speciﬁc CWNAs, and several
review articles have described the history and protective ratios of med-
ical countermeasures to OP intoxication (Dawson, 1994; Stojiljković
and Jokanović, 2006; Worek et al., 2007; Antonijevic and Stojiljkovic,
2007). In the following discussion, we review each of the oximes tested
in the present study within the context of those historical data. It is im-
portant to note that since these historical data have been obtained
under vastly different experimental conditions, e.g., different animal
species, doses, timing and routes of administration of the oxime, adju-
vants, or challenge materials, the results may not be directly compara-
ble. It is the result of this variability in procedures that necessitated
the evaluation of promising oximes within a single study in a standard-
ized and comparable manner.
2-PAM Cl, ﬁrst synthesized in 1955 (Childs et al., 1955), is a
monopyridinium oxime with the aldoximide in the 2-position. In clini-
cal settings, the use of 2-PAMCl is contraindicated (Wille et al., 2013) or
at least controversial (Rosman et al., 2009) against some pesticide in-
toxication. In the present study, 2-PAM Cl offered signiﬁcant survival
protection against LD85 challenges of GB, VX, and the pesticide oxons;
however signiﬁcant AChE reactivation was observed only for GB and
VX. These data are consistent with the less than optimal utility of 2-
PAM Cl against GA, GD, and GF observed in this study, and underscore
the need for a second generation reactivator for use in the U.S. In vitro
reactivation studies using human AChE indicated that 2-PAM Cl was
generally the least effective against GA, GB, GF, and VX relative to
HLö-7, HI-6, MMB4, and obidoxime (Worek et al., 2007) when com-
pared to the other oximes. A similar study by Cadieux et al. (2010)
also indicated less than optimal in vitro reactivation against GA, GB,
GF, VX, and Russian VX (VR) relative to HI-6 and MMB4.
In the present study, MMB4 DMS offered signiﬁcant protection in
terms of survivability against all of the OPs at both the equimolar and
TI dose levels except GD, likely due to rapid “aging” (irreversible
dealkylation of an alkoxy chain on the phosphorus atom) of the GD/
AChE conjugate (Vale, 2009). In terms of reactivation of blood AChE
and BChE 24-hour post-challenge, MMB4 DMS was superior to the
other seven oximes tested.
Similar to MMB4 DMS, HLö-7 DMS (at 146 μmol/kg given at 1 min
after challenge) was signiﬁcantly effective against every OP challenge
except GD as well. These results concur with the literature in that
HLö-7 DMS is a very good candidate for treatment of most OPs (Eyer
et al., 1992). Even prophylactically, HLö-7 diiodide at 43 μmol/kg by in-
traperitoneal injection (IP)was effective for reactivating diaphragmChE
inhibition by the G agents in atropinized mice (Clement et al., 1992).
HI-6 is available both as a dichloride or dimethanesulfonate salt. The
dichloride form of HI-6 is moderately effective in vitro at reactivating
GB-inhibited rat AChE (Esposito et al., 2014), whereas the dimethane-
sulfonate salt was shown to be superior in terms of both solubility in
biocompatible vehicles and biodistribution (Kuca et al., 2007b). HI-6
historically is a potent in vitro reactivator of GD- and GF- but not GA-
inhibited AChE (Lundy et al., 1992; Clement et al., 1992; Worek et al.,
2007; Esposito et al., 2014). Some have even stated that HI-6, despite
poor activity against GA, is as close to a broad-spectrum oxime as any(Soukup et al., 2013). In the present study, HI-6 DMS at 146 μmol/kg
was signiﬁcantly effective in promoting survival against GA, GB, GF,
and paraoxon, but did not possess as broad a spectrum of activity as
did MMB4 DMS or HLö-7 DMS. At the TI dose level (245 μmol/kg)
similar results were seen as compared to the equimolar treatment,
except with paraoxon where the TI therapy was not effective.
Obidoxime dichloride offered signiﬁcant survival protection against
GA, (nearly GB, p = 0.0515), VX, and each of the pesticide oxons,
conﬁrming historical data. In vitro tests showed that obidoxime was a
relatively poor reactivator of rat GA/AChE and GF/AChE conjugates,
was a moderate reactivator against GB, but performed well against VX
(Esposito et al., 2014). Obidoxime has exhibited ChE reactivation activ-
ity against the pesticides chlorpyrifos (Musilek et al., 2005), parathion,
and oxydemeton-methyl (Thiermann et al., 1997).
RS194B is a relatively new compound, the most effective among a
class of unchargedN-substituted 2-hydroxyiminoacetamido alkylamine
compounds tested in mice (Radić et al., 2012). However, at the equi-
molar to 2-PAMCl level of 146 μmol/kg, a signiﬁcant increase in survival
was observed only against GB in the present study. However, signiﬁcant
survival was seen against GB and chlorpyrifos oxon at the TI dose level
(281 μmol/kg).
Since TMB-4 was lethal at 146 μmol/kg in atropinized guinea pigs in
the present study, the treatment dose was reduced to 35 μmol/kg (20%
of the IM LD50) for evaluations. TMB-4 at 35 μmol/kg signiﬁcantly im-
proved survival rates only against LD85 challenge doses of VX and para-
oxon, but signiﬁcant reactivation of blood AChE was observed only
against VX, paraoxon, GB, and CPO. These observations are partially in
agreement with those observed by others, where TMB-4 offered high
reactivation of rat AChE inhibited by either GA, GB, or VX but not GF
(Esposito et al., 2014).
MINA was the only non-heterocyclic oxime tested in the present
study. This oxime is also capable of diffusion across the BBB (Skovira
et al., 2010). Here, protection by MINA alone at the equimolar dose
did not reach statistical signiﬁcance against all OPs tested. However, at
the TI dose level (74 μmol/kg) signiﬁcant protection was seen with
complete survival against both GB and VX. MINA has been shown to
offer signiﬁcant protection (the lower 95% conﬁdence limits for each
PR were N1) against GB, GF, and VX both with and without atropine
therapy, but only at much higher levels (402, 689, and 1148 μmol/kg).
While MINA affords protection against GB and VX, it is a relatively
poor reactivator of both AChE and BChE. Protection by MINA was
evident when coadministered with atropine and 2-PAM Cl therapies,
though this may be related to concurrent reactivation of peripheral and
central cholinesterase by 2-PAM Cl and MINA, respectively (Skovira
et al., 2010).
Conclusion
Collectively, the oxime reactivators MMB4 and HLö-7 were the
most efﬁcacious of all the oximes evaluated across the spectrum of
eight subcutaneously administered OPs tested. In terms of overall best
efﬁcacy performance based on 24-hour survivability, QOL, and blood
cholinesterase levels, using the standardized equimolar (146 μmol/kg)
approach, treatments of the dimethanesulfonate salts of MMB4 and
HLö-7 offered the most protection. Additionally, none of the oximes
evaluated at their TI dose exhibited protection levelsmatching those ex-
hibited byMMB4andHLö-7 at the standardized equimolar dose. 2-PAM
chloride, obidoxime dichloride, and HI-6 DMS were identiﬁed in the
second efﬁcacy tier, and RS194B and MINA offered the least general
protection in a third efﬁcacy tier. TMB-4 was tested at 35 μmol/kg due
to its toxicity and offered survival protection between the second and
third tiers.
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